CBDepot and CB21 Pharma webinar on Czech-sourced cGMP cannabinoid APIs

news-releasesCBDepot s.r.o.

October 16th 2023

Prague, Czechia: – Industry-leading cannabinoid ingredient specialists CBDepot and sister company CB21 Pharma will join forces later this month to host a webinar on the advantages of the Czech Republic as a source for fully certified pharma-grade cannabinoid ingredients.

The October 17 webinar ‘Czech-Made EU GMP Cannabis-Derived APIs’ will be hosted on the Arena events platform as a free to register event with registration available online.

The journey to cGMP production

The one-hour webinar session will commence at 1600 CST (UTC +2) and will feature contributions from key figures in both CBDepot and CB21 who have been instrumental in establishing ethical cannabis production In Czechia.

The session will be hosted by Michal Tözsér, Marketing Director for CBDepot/CB21, with observations from the companies’ CEO Jan Storch and Global Substance Sales Director, Boris Bañas.

The webinar will discuss the journey to fully certified cannabinoid production from CBDepot’s role from 2015 as a pioneering supplier of Czech made HACCP food grade CBD to CB21 Pharma new status as a fully EU GMP certified producer of pharma-grade CBD extracts as EU Ph. APIs.

Advantages and applications

It will also cover aspects such as:

Meeting the challenges of sourcing properly certified cannabis-derived ingredients for clinical trials
Introduction of CB21 Pharma’s EU GMP certified product portfolio of pharma-grade CBD, CBD API, Cannabis Extract API, and Dronabinol
Potential applications for these EUDRA-listed certified pharma-grade cannabis extracts for pharmacy compounded preparations, clinical trials and medicine development.

CBDepot and CB21 will also be joint exhibitors at the upcoming CPHI Barcelona on October 24-26, ready to discuss projects featuring cannabinoid-based ingredients.

About CBDepot and CB21 Pharma

Founded in 2015, CBDepot has established itself as a pioneering producer and B2B supplier of upmarket cannabinoid solutions, playing a leading role in creating legal and quality standards for cannabinoid ingredients and the formulation of cannabidiol derivatives.

With its sister company, CB21 Pharma, this Czech group of innovative companies serves fast-growing markets in the food, cosmetics, pharmaceuticals, and health products sectors with high-quality natural and synthesized cannabinoids and cannabis-derived ingredients.

CBDepot’s current strapline “Upmarket Cannabinoid Solutions “reflects its new ability to offer cannabinoid ingredients and substances to various markets such as: cosmetic, food, and food supplements, with Europe-wide recognition as a strong, ethical and transparent supplier of cannabinoids. Meanwhile, CB21 Pharma has become a fully certified pharmaceutical company that manufactures cannabis-derived isolates and extracts to EU GMP standards.

CB21 Pharma is a pharmaceutical company established in autumn 2018. It focuses on developing treatments based on non-psychotropic cannabinoids combined with other active substances and has pioneered innovative medical therapies and functional cosmetics.

The companies share a common heritage and many key personnel, including Chief Sales Officer, Boris Baňas, formerly a board member of the European Industrial Hemp Association (EIHA), where he successfully campaigned for the establishment of new Europe-wide standards. CBDepot’s scientific knowledge is based on close links with the Czech Academy of Sciences.

Learn more at www.cbdepot.eu